Sigma Polis

History

2022: Launch of the production of medical products for surgery and arthrology for 70 million rubles in the Technopolice

In mid-February 2022, it became known about the launch in the special economic zone (SEZ) of Technopolice of the production of medical for surgery and arthrology. This is a project of Sigma Policy, which invests about 70 million rubles in it.

The first products will enter the Russian market in 2022. It is planned that during the year the company will release 960 thousand units of drugs for autoplasmotherapy and 240 thousand units of packaging for sterilization and storage of endoprostheses. And in 2023, articular fluid substitutes and synthetic vessels will begin to be produced here. Finished products will be delivered to clinics and medical centers, as well as to retail pharmacy chains.

In the SEZ "Technopolice" launched the production of medical products for surgery and arthrology for 70 million rubles

As the head of the Moscow Department of Investment and Industrial Policy, Alexander Prokhorov, noted, Sigma Policy intends to produce products that are not inferior in quality to foreign counterparts. A total of 30 jobs will be created for the work of the new production line, said Vladimir Efimov, deputy mayor of Moscow for economic policy and property and land relations, whose words are quoted in the press service of the relevant complex of the capital's government. He specified that the production was launched on the basis of the existing enterprise for the manufacture of medical test systems.

According to data from the SPARK-Interfax system, Sigma Policy LLC was registered in March 2021. By mid-February 2022, the share of 51% of the legal entity belongs to the co-owner and general director of resident Skolkovo - Sigma Lab company Almaz Bekbaev, another 49% - Vladimir Mazyrko, financial indicators are not disclosed.

Earlier, Sigma Lab began mass production of Russian-Japanese express tests on COVID-19 developed by Genetic Technologies LLC and K.K. Mirai Gemonics.^[1]

Notes